We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Sue
Caton
s.caton@mmu.ac.uk
Sue
Caton
s.caton@mmu.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Disorders of psychological development
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
This is a small add-on study that is part of a larger co-produced project that aims to develop a toolkit of resources and guidance to support shared decision-making for adults with learning disabilities in relation to mental health medication prescribing and usage.
People with learning disabilities in England are more likely to be diagnosed with mental health problems and disproportionately prescribed psychotropic medications (including antipsychotics; antidepressants; anxiolytics; antiepileptics) compared to other people. People with learning disabilities in England are more likely than other people to be diagnosed with and severe mental illness, with rates increasing over time and frequently higher rates in Northern England (NHS Digital, 2021). Multiple medications have the short-term potential for harmful drug-drug interactions and long-term risks of side effects which can contribute to increased health service usage and high mortality rates (Heslop et al 2021). People with learning disabilities are highly compliant with psychotropic medications despite not always knowing why they are taking them or being aware of their right to be involved in decision-making.
This coproduced project will work with coresearchers with learning disabilities and collaborating self-advocacy organisations. The work will include interviews (N = 8) with independent or medical prescribers to explore their experiences of prescribing mental health medications for adults with learning disabilities. An online survey for independent or medical prescribers (N = 50) will broaden participation in relation to informing the development of resources for the toolkit. The toolkit will be developed using additional data from the wider project from people with learning disabilities, paid and family carers. The toolkit will be shared widely (e.g., through organisations such as RCGPs and the STOMP Programme) with the aim of raising awareness and embedding in organisational approaches.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Qualitative;
You can take part if:
You may not be able to take part if:
Interviews: • Prescribers who have not prescribed mental health medications to someone with a learning disability in the last 12 months • Prescribers who work outside of England Surveys: • Prescribers who have not prescribed mental health medications to someone with a learning disability in the last 12 months • Prescribers who work outside of England
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Sue
Caton
s.caton@mmu.ac.uk
Sue
Caton
s.caton@mmu.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by LANCASHIRE & SOUTH CUMBRIA NHS FOUNDATION TRUST and funded by NIHR Central Commissioning Facility (CCF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 59268
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
